Collegium Pharmaceutical
COLL
eBay
EBAY
Halozyme Therapeutics
HALO
SilverCrest Metals
SILV
Workday
WDAY
(Q3)Sep 30, 2020 | (Q2)Jun 30, 2020 | (Q1)Mar 31, 2020 | (FY)Dec 31, 2019 | (Q4)Dec 31, 2019 | (Q3)Sep 30, 2019 | (Q2)Jun 30, 2019 | (Q1)Mar 31, 2019 | (FY)Dec 31, 2018 | (Q4)Dec 31, 2018 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 53.17%-5.7M | 5.24%18.48M | 412.67%21.15M | 50.64%-14.88M | -78.54%-13.51M | -1.27%-12.17M | 342.92%17.56M | -102.82%-6.76M | -1,618.53%-30.14M | -9.65%-7.56M |
Net income from continuing operations | -131.15%-30.02M | 16.34%-4.41M | 170.53%10.07M | 62.03%-22.61M | 56.77%-8.08M | 42.62%-12.99M | 70.47%-5.27M | 1,051.92%3.72M | -50.19%-59.56M | -11.30%-18.7M |
Operating gains losses | -122.85%-281K | 36.67%-342K | 793.41%5.05M | -54.20%1.63M | 8.85%1.67M | 784.89%1.23M | -128.21%-540K | -3,366.67%-728K | 654.04%3.57M | 368.06%1.54M |
Depreciation and amortization | 5.24%3.23M | 4.84%3.97M | 74.97%5.31M | 7.62%13.63M | -20.45%3.74M | -0.65%3.07M | 59.65%3.78M | 21.33%3.03M | 4.64%12.66M | 67.92%4.7M |
Deferred tax | --0 | --0 | 364.23%9.4M | 95.48%3.24M | -91.79%124K | --0 | 1,691.80%1.09M | 202,300.00%2.02M | 72.89%1.66M | --1.51M |
Other non cash items | 1,197.01%12.58M | 11.86%1.06M | 12.16%1.03M | -31.14%3.83M | -31.24%997K | -56.19%970K | 40.48%944K | -25.06%921K | -74.06%5.57M | -15.50%1.45M |
Change In working capital | 234.15%6.84M | 11.14%17.75M | 35.53%-11.27M | -153.93%-16.25M | -1,958.77%-9.65M | -267.24%-5.1M | 634.59%15.97M | -126.81%-17.48M | -402.93%-6.4M | -85.70%519K |
-Change in receivables | ---- | ---- | ---- | -102.18%-25.8M | ---- | ---- | ---- | ---- | -169.89%-12.76M | ---- |
-Change in prepaid assets | ---- | ---- | ---- | -394.24%-2.55M | ---- | ---- | ---- | ---- | 157.45%868K | ---- |
-Change in payables and accrued expense | ---- | ---- | ---- | 282.94%19.41M | ---- | ---- | ---- | ---- | 127.72%5.07M | ---- |
-Change in other working capital | ---- | ---- | ---- | -1,828.37%-7.31M | ---- | ---- | ---- | ---- | -88.42%423K | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 53.17%-5.7M | 5.24%18.48M | 412.67%21.15M | 50.64%-14.88M | -78.54%-13.51M | -1.27%-12.17M | 342.92%17.56M | -102.82%-6.76M | -1,618.53%-30.14M | -9.65%-7.56M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 123.98%129K | -364.62%-688K | 58.15%-77K | 105.44%1.21M | 2,666.15%1.67M | 97.51%-538K | 146.59%260K | -483.33%-184K | -2,818.55%-22.18M | 82.76%-65K |
Net PPE purchase and sale | 123.98%129K | -364.62%-688K | 58.15%-77K | 379.17%1.21M | 2,666.15%1.67M | -476.22%-538K | 146.59%260K | -483.33%-184K | 43.16%-432K | 82.76%-65K |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---21.75M | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 123.98%129K | -364.62%-688K | 58.15%-77K | 105.44%1.21M | 2,666.15%1.67M | 97.51%-538K | 146.59%260K | -483.33%-184K | -2,818.55%-22.18M | 82.76%-65K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -1,152.70%-779K | 269.87%2.27M | -299.42%-17.56M | -80.00%11.35M | 179.31%3.81M | -99.85%74K | -34.07%-1.33M | -32.85%8.81M | 1,018.97%56.77M | -52.40%-4.8M |
Net issuance payments of debt | -194.17%-776K | 2,818.81%5.93M | -261.17%-15.24M | -76.90%14.83M | 262.40%4.77M | -98.45%824K | ---218K | -32.48%9.46M | 7,233.78%64.2M | -418.78%-2.94M |
Net common stock issuance | --0 | --0 | --0 | 84.83%-266K | --0 | --0 | ---366K | 157.14%100K | -1,451.33%-1.75M | --0 |
Net other financing activities | 99.60%-3K | -388.13%-3.66M | -209.47%-2.32M | 43.42%-3.21M | 48.36%-962K | 64.32%-750K | 24.62%-750K | -4.60%-750K | -9.91%-5.68M | 54.23%-1.86M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -1,152.70%-779K | 269.87%2.27M | -299.42%-17.56M | -80.00%11.35M | 179.31%3.81M | -99.85%74K | -34.07%-1.33M | -32.85%8.81M | 1,018.97%56.77M | -52.40%-4.8M |
Net cash flow | ||||||||||
Beginning cash position | 7.82%28.24M | -11.50%8.62M | -29.75%5.52M | 110.23%7.85M | -33.14%13.64M | 469.93%26.19M | -27.77%9.74M | 110.23%7.85M | -69.35%3.73M | 44.92%20.39M |
Current changes in cash | 49.74%-6.35M | 21.67%20.06M | 88.97%3.51M | -152.18%-2.32M | 35.38%-8.03M | -179.79%-12.63M | 287.72%16.48M | -81.09%1.86M | 151.20%4.45M | -19.22%-12.43M |
Effect of exchange rate changes | 128.38%169K | -1,393.10%-433K | -1,412.90%-407K | 96.11%-13K | 22.61%-89K | 305.56%74K | 72.64%-29K | 140.26%31K | -236.33%-334K | -16.16%-115K |
End cash Position | 61.80%22.06M | 7.82%28.24M | -11.50%8.62M | -29.75%5.52M | -29.75%5.52M | -33.14%13.64M | 469.93%26.19M | -27.77%9.74M | 110.23%7.85M | 110.23%7.85M |
Free cash flow | 54.27%-5.82M | 2.58%17.73M | 394.26%20.87M | 40.44%-18.71M | -107.83%-16.17M | -3.01%-12.73M | 321.71%17.29M | -104.41%-7.09M | -609.88%-31.41M | -7.78%-7.78M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |